Indolent B cell lymphoma

Common Name(s)

Indolent B cell lymphoma

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Indolent B cell lymphoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Indolent B cell lymphoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Indolent B cell lymphoma" returned 33 free, full-text research articles on human participants. First 3 results:

Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma.
 

Author(s): Andrew J Cowan, Phillip A Stevenson, Ted A Gooley, Shani L Frayo, George R Oliveira, Stephen D Smith, Damian J Green, Jennifer E Roden, John M Pagel, Brent L Wood, Oliver W Press, Ajay K Gopal

Journal: Br. J. Haematol.. 2017 02;176(4):583-590.

 

Fenretinide, a synthetic retinoid, induces apoptotic cell death in B-cell non-Hodgkin lymphoma (B-NHL) and acts synergistically with rituximab in preclinical models. We report results from a phase I-II study of fenretinide with rituximab for B-NHLs. Eligible diagnoses included indolent ...

Last Updated: 31 Dec 1969

Go To URL
Introduction to a review series: the paradox of indolent B-cell lymphoma.
 

Author(s): Laurie H Sehn

Journal: Blood. 2016 04;127(17):2045-6.

 

Last Updated: 31 Dec 1969

Go To URL
Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
 

Author(s): H Saito, D Maruyama, A M Maeshima, S Makita, H Kitahara, K Miyamoto, S Fukuhara, W Munakata, T Suzuki, Y Kobayashi, H Taniguchi, K Tobinai

Journal:

 

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Indolent B cell lymphoma" returned 3 free, full-text review articles on human participants. First 3 results:

Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.
 

Author(s): Michele Merli, Giuseppe Carli, Luca Arcaini, Carlo Visco

Journal: World J. Gastroenterol.. 2016 Oct;22(38):8447-8458.

 

The association of hepatitis C virus (HCV) and B-cell non-Hodgkin lymphomas (NHL) has been highlighted by several epidemiological and biological insights; however the most convincing evidence is represented by interventional studies demonstrating the capability of antiviral treatment ...

Last Updated: 31 Dec 1969

Go To URL
The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma.
 

Author(s): John Kuruvilla

Journal: Blood. 2016 04;127(17):2093-100.

 

Despite improvements over the past decade in the overall survival of patients with indolent non-Hodgkin lymphomas, these lymphomas remain largely incurable with standard therapies. Immunochemotherapy with rituximab-based regimens has become a well-established standard of care in the ...

Last Updated: 31 Dec 1969

Go To URL
Pathology of indolent B-cell neoplasms other than follicular lymphoma.
 

Author(s): Seiji Sakata, Naoko Tsuyama, Kengo Takeuchi

Journal: J Clin Exp Hematop. 2014 ;54(1):11-22.

 

Indolent B-cell lymphomas include follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and marginal zone lymphomas (MZLs). They are a diverse group of disorders with different clinical, morphological, immunophenotypic and genetic features. However, ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Indolent Non Follicular Lymphomas Prognostic Project
 

Status: Recruiting

Condition Summary: Indolent B-Cell Lymphomas

 

Last Updated: 12 Oct 2017

Go to URL
Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection
 

Status: Recruiting

Condition Summary: Indolent B-cell Lymphoma; Hepatitis C

 

Last Updated: 13 Nov 2017

Go to URL
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
 

Status: Recruiting

Condition Summary: Chronic Lymphocytic Leukemia; Indolent B-cell Lymphomas; Chronic Hepatitis B; Lymphoma, Small Lymphocytic; Mantle-Cell Lymphoma; Waldenstrom's Macroglobulinaemia; Follicular Lymphoma

 

Last Updated: 8 Dec 2016

Go to URL